MARKET

MGNX

MGNX

Macrogenics Inc
NASDAQ
6.92
+0.49
+7.62%
After Hours: 6.92 0 0.00% 17:00 12/01 EST
OPEN
6.59
PREV CLOSE
6.43
HIGH
7.22
LOW
6.50
VOLUME
1.46M
TURNOVER
0
52 WEEK HIGH
18.25
52 WEEK LOW
2.130
MARKET CAP
425.41M
P/E (TTM)
-2.2274
1D
5D
1M
3M
1Y
5Y
Here's How to Find Cheap Stocks Under $10 to Buy for December
Use one of our Zacks screens to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying heading into December and beyond...
Zacks · 2d ago
7 Analysts Have This to Say About Macrogenics
Benzinga · 11/23 19:01
Expert Ratings for Macrogenics
Benzinga · 11/23 17:02
Baidu To $180? Plus This Analyst Cuts PT On MacroGenics By 56%
Benzinga · 11/23 15:56
Burlington Stores To Surge Over 21%? Plus Wedbush Slashes PT On Jack In The Box
Benzinga · 11/23 13:58
What 7 Analyst Ratings Have To Say About Macrogenics
Benzinga · 11/23 13:02
Where Macrogenics Stands With Analysts
Benzinga · 11/23 12:03
Citigroup Downgrades Macrogenics to Neutral, Lowers Price Target to $7
Benzinga · 11/23 11:25
More
About MGNX
MacroGenics, Inc. is a biopharmaceutical company that is focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. It is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

Webull offers kinds of MacroGenics Inc stock information, including NASDAQ:MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.